{'52WeekChange': -0.118320584,
 'SandP52WeekChange': 0.0644362,
 'address1': '2 Gansevoort Street',
 'address2': '9th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.41,
 'askSize': 900,
 'averageDailyVolume10Day': 2931812,
 'averageVolume': 650266,
 'averageVolume10days': 2931812,
 'beta': 2.062345,
 'beta3Year': None,
 'bid': 2.31,
 'bidSize': 1400,
 'bookValue': 0.295,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.45,
 'dayLow': 2.29,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': 45.406,
 'enterpriseValue': 105705304,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 2.0514286,
 'fiftyTwoWeekHigh': 3.34,
 'fiftyTwoWeekLow': 1.05,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 40346689,
 'forwardEps': -0.44,
 'forwardPE': -5.25,
 'fromCurrency': None,
 'fullTimeEmployees': 8,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.3143,
 'heldPercentInstitutions': 0.12211,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/checkpointtx.com',
 'longBusinessSummary': 'Checkpoint Therapeutics, Inc., an immuno-oncology '
                        'biopharmaceutical company, focuses on the '
                        'acquisition, development, and commercialization of '
                        'novel treatments for patients with solid tumor '
                        "cancers. The company's product candidates include "
                        'CK-101 that in Phase I clinical trial for the '
                        'treatment of epidermal growth factor receptor '
                        'mutation-positive non-small cell lung cancer; and '
                        'Cosibelimab, a programmed death ligand-1 (PD-L1), '
                        'which is in Phase I clinical trial in patients with '
                        'selected recurrent or metastatic cancers. It also '
                        'develops CK-103, a small molecule inhibitor of BET '
                        'bromodomains; and CK-302, a human agonistic antibody '
                        'for oncology indications. Checkpoint Therapeutics, '
                        'Inc. has collaboration agreements with TG '
                        'Therapeutics, Inc. to develop and commercialize '
                        'certain assets in connection with its licenses in the '
                        'field of hematological malignancies. The company was '
                        'founded in 2014 and is headquartered in New York, New '
                        'York. Checkpoint Therapeutics, Inc. is a subsidiary '
                        'of Fortress Biotech, Inc.',
 'longName': 'Checkpoint Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 127186288,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_286675384',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -22105000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.4217,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '781 652 4500',
 'previousClose': 2.43,
 'priceHint': 4,
 'priceToBook': 7.8305087,
 'priceToSalesTrailing12Months': 54.633286,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.45,
 'regularMarketDayLow': 2.29,
 'regularMarketOpen': 2.4217,
 'regularMarketPreviousClose': 2.43,
 'regularMarketPrice': 2.4217,
 'regularMarketVolume': 496266,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 48038500,
 'sharesPercentSharesOut': 0.0163,
 'sharesShort': 896320,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 726712,
 'shortName': 'Checkpoint Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0227,
 'shortRatio': 3.31,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'CKPT',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.553,
 'twoHundredDayAverage': 1.827518,
 'volume': 496266,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.checkpointtx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10014'}